Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

George Daniel Demetri, M.D.

Co-Author

This page shows the publications co-authored by George Demetri and Jonathan Fletcher.
Connection Strength

5.151
  1. Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network. Ann Oncol. 2020 11; 31(11):1506-1517.
    View in: PubMed
    Score: 0.235
  2. Cyclin D1 is a mediator of gastrointestinal stromal tumor KIT-independence. Oncogene. 2019 09; 38(39):6615-6629.
    View in: PubMed
    Score: 0.218
  3. Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours. Br J Cancer. 2019 Jul; 121(3):281.
    View in: PubMed
    Score: 0.217
  4. Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours. Br J Cancer. 2019 03; 120(6):612-620.
    View in: PubMed
    Score: 0.211
  5. MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation. Nat Commun. 2017 03 08; 8:14674.
    View in: PubMed
    Score: 0.184
  6. Dystrophin is a tumor suppressor in human cancers with myogenic programs. Nat Genet. 2014 Jun; 46(6):601-6.
    View in: PubMed
    Score: 0.151
  7. KRAS and KIT Gatekeeper Mutations Confer Polyclonal Primary Imatinib Resistance in GI Stromal Tumors: Relevance of Concomitant Phosphatidylinositol 3-Kinase/AKT Dysregulation. J Clin Oncol. 2015 Aug 01; 33(22):e93-6.
    View in: PubMed
    Score: 0.151
  8. Genome-wide functional screening identifies CDC37 as a crucial HSP90-cofactor for KIT oncogenic expression in gastrointestinal stromal tumors. Oncogene. 2014 Apr 03; 33(14):1872-6.
    View in: PubMed
    Score: 0.141
  9. Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. J Clin Oncol. 2012 Jul 01; 30(19):2401-7.
    View in: PubMed
    Score: 0.132
  10. A multicenter phase II study of regorafenib in patients (pts) with advanced gastrointestinal stromal tumor (GIST), after therapy with imatinib (IM) and sunitinib (SU). J Clin Oncol. 2011 May 20; 29(15_suppl):10007.
    View in: PubMed
    Score: 0.123
  11. An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) in patients (pts) with metastatic and/or unresectable GIST. J Clin Oncol. 2011 May 20; 29(15_suppl):10011.
    View in: PubMed
    Score: 0.123
  12. Strong expression of IGF1R in pediatric gastrointestinal stromal tumors without IGF1R genomic amplification. Int J Cancer. 2010 Dec 01; 127(11):2718-22.
    View in: PubMed
    Score: 0.119
  13. Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. Clin Cancer Res. 2009 Sep 15; 15(18):5902-9.
    View in: PubMed
    Score: 0.110
  14. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol. 2008 Nov 20; 26(33):5360-7.
    View in: PubMed
    Score: 0.103
  15. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol. 2008 Nov 20; 26(33):5352-9.
    View in: PubMed
    Score: 0.103
  16. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol. 2008 Sep; 216(1):64-74.
    View in: PubMed
    Score: 0.102
  17. Protein kinase C-theta regulates KIT expression and proliferation in gastrointestinal stromal tumors. Oncogene. 2008 Sep 18; 27(42):5624-34.
    View in: PubMed
    Score: 0.101
  18. Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res. 2007 Sep 15; 13(18 Pt 1):5398-405.
    View in: PubMed
    Score: 0.096
  19. KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway. Oncogene. 2007 Nov 29; 26(54):7560-8.
    View in: PubMed
    Score: 0.094
  20. KIT oncoprotein interactions in gastrointestinal stromal tumors: therapeutic relevance. Oncogene. 2007 Sep 27; 26(44):6386-95.
    View in: PubMed
    Score: 0.093
  21. Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res. 2006 Sep 15; 66(18):9153-61.
    View in: PubMed
    Score: 0.089
  22. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol. 2006 Oct 10; 24(29):4764-74.
    View in: PubMed
    Score: 0.089
  23. Evaluation of SRC-family kinases in gastrointestinal stromal tumors. J Clin Oncol. 2006 Jun 20; 24(18_suppl):9529.
    View in: PubMed
    Score: 0.088
  24. Sunitinib (SU) response in imatinib-resistant (IM-R) GIST correlates with KIT and PDGFRA mutation status. J Clin Oncol. 2006 Jun 20; 24(18_suppl):9502.
    View in: PubMed
    Score: 0.088
  25. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol. 2006 Mar 01; 24(7):1195-203.
    View in: PubMed
    Score: 0.086
  26. Results from a continuation trial of SU11248 in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST). J Clin Oncol. 2005 Jun; 23(16_suppl):9011.
    View in: PubMed
    Score: 0.082
  27. Clinical benefit of imatinib in patients (pts) with metastatic gastrointestinal stromal tumors (GIST) negative for the expression of CD117 in the S0033 trial. J Clin Oncol. 2005 Jun; 23(16_suppl):9010.
    View in: PubMed
    Score: 0.082
  28. Phase I dose-escalation study of the SRC and multi-kinase inhibitor BMS-354825 in patients (pts) with GIST and other solid tumors. J Clin Oncol. 2005 Jun; 23(16_suppl):3034.
    View in: PubMed
    Score: 0.082
  29. Correlation of target kinase genotype with clinical activity of imatinib mesylate (IM) in patients with metastatic GI stromal tumors (GISTs) expressing KIT (KIT+). J Clin Oncol. 2005 Jun; 23(16_suppl):7.
    View in: PubMed
    Score: 0.082
  30. Aneurysmal bone cyst variant translocations upregulate USP6 transcription by promoter swapping with the ZNF9, COL1A1, TRAP150, and OMD genes. Oncogene. 2005 May 12; 24(21):3419-26.
    View in: PubMed
    Score: 0.081
  31. Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindred. J Clin Oncol. 2005 Apr 20; 23(12):2735-43.
    View in: PubMed
    Score: 0.081
  32. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol. 2005 Feb 01; 23(4):866-73.
    View in: PubMed
    Score: 0.080
  33. Protein Kinase C theta (PKCtheta) expression and constitutive activation in gastrointestinal stromal tumors (GISTs). Cancer Res. 2004 Aug 01; 64(15):5127-31.
    View in: PubMed
    Score: 0.077
  34. Clonal evolution of resistance to imatinib (IM) in patients (pts) with gastrointestinal stromal tumor (GIST): molecular and radiologic evaluation of new lesions. J Clin Oncol. 2004 Jul 15; 22(14_suppl):3010.
    View in: PubMed
    Score: 0.077
  35. SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST). J Clin Oncol. 2004 Jul 15; 22(14_suppl):3001.
    View in: PubMed
    Score: 0.077
  36. Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene. 2004 May 13; 23(22):3999-4006.
    View in: PubMed
    Score: 0.076
  37. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003 Dec 01; 21(23):4342-9.
    View in: PubMed
    Score: 0.074
  38. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003 Jan 31; 299(5607):708-10.
    View in: PubMed
    Score: 0.069
  39. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol. 2002 Sep 15; 20(18):3898-905.
    View in: PubMed
    Score: 0.068
  40. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002 Aug 15; 347(7):472-80.
    View in: PubMed
    Score: 0.067
  41. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 2001 Nov 15; 61(22):8118-21.
    View in: PubMed
    Score: 0.064
  42. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene. 2001 Aug 16; 20(36):5054-8.
    View in: PubMed
    Score: 0.063
  43. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol. 2000 Mar; 156(3):791-5.
    View in: PubMed
    Score: 0.057
  44. Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors. Clin Cancer Res. 2019 12 15; 25(24):7287-7293.
    View in: PubMed
    Score: 0.055
  45. Gastrointestinal stromal tumor enhancers support a transcription factor network predictive of clinical outcome. Proc Natl Acad Sci U S A. 2018 06 19; 115(25):E5746-E5755.
    View in: PubMed
    Score: 0.050
  46. Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol. 2017 Jul 01; 3(7):944-952.
    View in: PubMed
    Score: 0.047
  47. Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy. Ann Oncol. 2016 09; 27(9):1794-9.
    View in: PubMed
    Score: 0.044
  48. Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma. Oncotarget. 2016 Mar 29; 7(13):16581-92.
    View in: PubMed
    Score: 0.043
  49. Key Issues in the Clinical Management of Gastrointestinal Stromal Tumors: An Expert Discussion. Oncologist. 2015 Jul; 20(7):823-30.
    View in: PubMed
    Score: 0.041
  50. c-Jun promotes cell migration and drives expression of the motility factor ENPP2 in soft tissue sarcomas. J Pathol. 2014 Oct; 234(2):190-202.
    View in: PubMed
    Score: 0.039
  51. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol. 2013 Sep 10; 31(26):3182-90.
    View in: PubMed
    Score: 0.036
  52. Aberrant AKT activation drives well-differentiated liposarcoma. Proc Natl Acad Sci U S A. 2011 Sep 27; 108(39):16386-91.
    View in: PubMed
    Score: 0.032
  53. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci U S A. 2011 Jan 04; 108(1):314-8.
    View in: PubMed
    Score: 0.030
  54. Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin Cancer Res. 2008 Dec 01; 14(23):7726-32.
    View in: PubMed
    Score: 0.026
  55. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin Cancer Res. 2008 May 01; 14(9):2717-25.
    View in: PubMed
    Score: 0.025
  56. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008 Feb 01; 26(4):620-5.
    View in: PubMed
    Score: 0.025
  57. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol. 2007 Jul; 8(7):595-602.
    View in: PubMed
    Score: 0.024
  58. High-throughput oncogene mutation profiling in human cancer. Nat Genet. 2007 Mar; 39(3):347-51.
    View in: PubMed
    Score: 0.023
  59. Soft tissue sarcomas of adults: state of the translational science. Clin Cancer Res. 2003 Jun; 9(6):1941-56.
    View in: PubMed
    Score: 0.018
  60. Synovial sarcoma: prognostic significance of tumor size, margin of resection, and mitotic activity for survival. J Clin Oncol. 1996 Apr; 14(4):1201-8.
    View in: PubMed
    Score: 0.011
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.